209 related articles for article (PubMed ID: 33902600)
1. Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration.
Chen Q; Fu L; Hu J; Guo G; Xie A
Cancer Cell Int; 2021 Apr; 21(1):235. PubMed ID: 33902600
[TBL] [Abstract][Full Text] [Related]
2. Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration.
He J; Xing J; Yang X; Zhang C; Zhang Y; Wang H; Xu X; Wang H; Cao Y; Xu H; Zhang C; Wang C; Yu E
Chemotherapy; 2019; 64(3):146-154. PubMed ID: 31715603
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1.
Duan X; Yang J; Jiang B; Duan W; Wei R; Zhang H; Mao X
Aging (Albany NY); 2021 Sep; 13(17):21325-21344. PubMed ID: 34499615
[TBL] [Abstract][Full Text] [Related]
4. PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K/Akt pathway.
Wang Z; Xiong H; Zuo Y; Hu S; Zhu C; Min A
Cell Cycle; 2022 Mar; 21(5):477-488. PubMed ID: 34979867
[TBL] [Abstract][Full Text] [Related]
5. PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration.
Song M; Wang Y; Zhang Z; Wang S
Oncotarget; 2017 Jan; 8(1):933-953. PubMed ID: 27888613
[TBL] [Abstract][Full Text] [Related]
6. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
Zhu D; Huang J; Liu N; Li W; Yan L
Cell Death Dis; 2021 Jul; 12(8):730. PubMed ID: 34294689
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
8.
Qin J; Wang W; An F; Huang W; Ding J
J Cancer; 2019; 10(20):4939-4946. PubMed ID: 31598166
[No Abstract] [Full Text] [Related]
9. PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma.
Yang Y; Qi F; Wei C; Liu J; Zhang Y; Luan W; Gu J
Cell Death Discov; 2021 Oct; 7(1):323. PubMed ID: 34716318
[TBL] [Abstract][Full Text] [Related]
10. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway.
Su J; Hu S; Ding S; Feng K
Cell Cycle; 2023 Nov; 22(21-22):2381-2391. PubMed ID: 38123344
[TBL] [Abstract][Full Text] [Related]
11. High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis.
Zhu D; Gu X; Lin Z; Yu D; Wang J
Oncogenesis; 2021 May; 10(5):43. PubMed ID: 34016944
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Wang Y; Zhu M; Li J; Xiong Y; Wang J; Jing H; Gu Y
Cell Death Dis; 2021 Jul; 12(7):690. PubMed ID: 34244472
[TBL] [Abstract][Full Text] [Related]
13. PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma.
Liu Y; Chen H; Li X; Zhang F; Kong L; Wang X; Bai J; Wu X
Front Oncol; 2021; 11():607021. PubMed ID: 33718159
[TBL] [Abstract][Full Text] [Related]
14. PSMC2/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma.
Duan X; Li H; Wang M; Ju S; Li F; Chen P; Lu H; Han X; Ren J
Cell Death Discov; 2021 Aug; 7(1):217. PubMed ID: 34413286
[TBL] [Abstract][Full Text] [Related]
15. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathway.
Wang Y; Zhang S; Zhao Z; Jin Q; Wang Z; Song Z; Liu L; Zhao Z
Immunobiology; 2024 Mar; 229(3):152802. PubMed ID: 38569452
[TBL] [Abstract][Full Text] [Related]
16. PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells.
Zheng X; Wang Y; Wang D; Wan J; Qin X; Mu Z; Hu N
World J Surg Oncol; 2022 Mar; 20(1):84. PubMed ID: 35287689
[TBL] [Abstract][Full Text] [Related]
17. PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway.
Liu T; Zhang J; Chen H; Bianba T; Pan Y; Wang X; Jiang Y; Yang Z
Oncogenesis; 2022 Mar; 11(1):12. PubMed ID: 35256584
[TBL] [Abstract][Full Text] [Related]
18. Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2.
Li GW; Yan X
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1915-1925. PubMed ID: 30915734
[TBL] [Abstract][Full Text] [Related]
19. SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway.
Liu Z; Wang Q; Zhai G; Ke S; Yu X; Guo J
Cancer Cell Int; 2022 Mar; 22(1):127. PubMed ID: 35305629
[TBL] [Abstract][Full Text] [Related]
20. CACYBP knockdown inhibits progression of prostate cancer via p53.
Li Q; Liu Z; Ma L; Yin W; Zhang K
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5761-5772. PubMed ID: 36576589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
